Century Therapeutics, Inc.
NASDAQ:IPSCBiotechnology
+$0.01 today
- Market cap
- $250.60M
- Beta
- 1.57
- P/E (TTM)
- -1.8
- EPS (TTM)
- -$1.25
Volume 1.14M
Average 1.12M
IPSC Operating Expenses
Total costs of running the business that are not directly tied to producing goods or services sold.
Century Therapeutics, Inc.NASDAQ: IPSC
Operating Expenses · Q1 FY2026 · quarter ended Mar 2026
Operating expenses declines year over year
Q1 FY2026 operating expenses of $22.5M fell 35.7% year over year, ahead of the -41.0% change in trailing-twelve-month operating expenses. Sequentially, it rose 8.9% from the prior quarter. Over 3 fiscal years it compounded at -7.2% a year.
Context
- Operating expenses amounted to 101.8% of revenue in FY2025, down 2094.7 pp from a year earlier.
- Operating expenses increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of -35.7% holds above the trailing-twelve-month pace of -41.0%.
Sources:Income StatementText generated from reported figures; not investment advice.
Operating Expenses history
USD · from the income statement
- Latest · FY2025
- 111.1M USD
- Year-over-year change
- -23.2%
- 4-year CAGR
- +5.3%
| Period | Period end | Operating Expenses | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 111.1M | -23.2% |
| FY2024 | 2024-12-31 | 144.73M | -2.7% |
| FY2023 | 2023-12-31 | 148.78M | +7.0% |
| FY2022 | 2022-12-31 | 139.03M | +54.0% |
| FY2021 | 2021-12-31 | 90.3M | — |
Operating Expenses vs competitors
How IPSC compares with its peers on the latest reported figures
- IPSC's LTM Mar 2026 operating expenses of $87.08M is the 2nd highest of the 8 companies compared; the peer median is $33.51M.
- Its year-over-year change of -41.0% is the 7th highest of 8, against a peer median of -10.3%.
- Over three fiscal years its annual growth of -7.2% compares with a peer median of -0.3%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $229.32M | -10.3% | -7.8% | 151.8% | |
| LTM Mar 2026 | $87.08M | -41.0% | -7.2% | — | |
| LTM Mar 2026 | $59.37M | -22.3% | +2.5% | 17821.9% | |
| LTM Mar 2026 | $52.24M | +6.3% | -0.3% | 159.6% | |
OSTXOS Therapies Incorporated | LTM Mar 2026 | $33.51M | +199.7% | +85.4% | — |
| LTM Mar 2026 | $20.3M | -54.6% | -32.8% | — | |
| LTM Mar 2026 | $14.13M | +26.1% | -25.3% | 999.7% | |
| LTM Mar 2026 | $9.39M | -25.3% | +131.1% | — | |
| Peer median (excluding IPSC) | $33.51M | -10.3% | -0.3% | 579.6% | |
Competitors are the stored peer set for IPSC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 5.2M | 2.24M | 6.59M | 109.16M |
| Cost of Revenue | 4.58M | 0 | 0 | 0 | 13.1M |
| Gross Profit | (4.58M) | 5.2M | 2.24M | 6.59M | 96.06M |
| Gross Margin | — | 100.0% | 100.0% | 100.0% | 88.0% |
| Research & Development | 75.65M | 97.17M | 92.71M | 107.24M | 95.67M |
| Selling, General & Admin | 14.65M | 31.86M | 34.71M | 33.16M | 24M |
| Operating Expenses | 90.3M | 139.03M | 148.78M | 144.73M | 111.1M |
| Depreciation & Amortization | 4.58M | 8.44M | 13.04M | 13.3M | 13.1M |
| EBITDA | (89.92M) | (121.2M) | (121.21M) | (111.47M) | 3.45M |
| EBITDA Margin | — | -2331.2% | -5423.2% | -1691.8% | 3.2% |
| Operating Income | (94.88M) | (133.83M) | (146.55M) | (138.14M) | (15.04M) |
| Operating Margin | — | -2574.2% | -6556.9% | -2096.5% | -13.8% |
| Interest Income | 898K | 2.99M | 12.68M | 13.01M | 7.35M |
| Interest Expense | 1.28M | 0 | 540K | 0 | 0 |
| Other Income / Expenses | (898K) | 2.99M | 11.75M | 13.36M | 5.39M |
| Income Before Tax | (95.78M) | (130.84M) | (134.79M) | (124.78M) | (9.65M) |
| Pre-Tax Margin | — | -2516.7% | -6031.0% | -1893.7% | -8.8% |
| Income Tax Expense | 43K | 91K | 1.88M | 1.79M | (68K) |
| Net Income | (95.82M) | (130.93M) | (136.67M) | (126.57M) | (9.58M) |
| Net Margin | — | -2518.4% | -6115.1% | -1920.9% | -8.8% |
| EPS (Basic) | (1.74) | (2.27) | (2.30) | (1.61) | (0.11) |
| EPS (Diluted) | (1.74) | (2.27) | (2.30) | (1.61) | (0.11) |
| Weighted Avg Shares | 55.01M | 57.76M | 59.31M | 78.65M | 86.56M |
| Weighted Avg Shares (Diluted) | 55.01M | 57.76M | 59.31M | 78.65M | 86.56M |
Century Therapeutics, Inc.
NASDAQ:IPSC
Intrinsic Alpha fair value
Locked
Current Price
$1.38
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.